600 patients66,869 observations120 daysLIVE

Patient P-01459

Synthetic patientNBL-101 · Day 108 · 35–44 · F · baseline S02Steering view · 3DOpen companion preview
Therapy response
Declining
Tolerance
Stable
GI state
Unstable
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
66%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S02
  2. Day 79 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 79.

Primary contributors, last 14 days
  • Treatment adherence-13
  • GI instability+7
  • Nutritional resilience-6
  • Toxicity+3
  • Inflammatory activity+2

What helped?

No interventions yet.

    LIFE OS recommendation
    GI Support Protocol GI-04
    67%
    probability of meaningful tolerance improvement
    • 284 similar trajectories
    • 83% showed improvement
    • median effect visible after 8 days

    Daily trackers

    Molecule settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    GI burden
    Companion
    61/100
    worsening · +12.3 vs previous 14 d
    Toxicity
    Blood
    49.8/100
    worsening · +11.4 vs previous 14 d
    Sleep quality
    Wearable
    29.7/100
    worsening · -5.4 vs previous 14 d
    Energy level
    Daily log
    2.7/10
    worsening · -1.0 vs previous 14 d
    Stress level
    Daily log
    7.5/10
    worsening · +1.0 vs previous 14 d
    Steps
    Wearable
    967
    worsening · -745 vs previous 14 d
    Adherence
    Companion
    63.8 %
    worsening · -13.3 vs previous 14 d
    This trajectory is decaying — what would help, what would not
    Steering view →

    Heading towards failing · 31 from the failing basin, 61 from restoration.

    Would help
    • GI-04 GI Support Protocol
      73% improved among 124 similar · onset 8 d · confidence 66%
    • ME-01 Monitoring Escalation
      100% improved among 75 similar · onset 3 d · confidence 73%
    • NP-02 Dietary Support Protocol
      65% improved among 62 similar · onset 10 d · confidence 73%
    Would not help
    • Keep histamine low
      GI +5.1 next day on high-intake days · n 26
    • Keep fat low
      GI +4 next day on high-intake days · n 25
    • Keep spicy low
      GI +3.9 next day on high-intake days · n 27
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Histamine load
      +5.1detractor · 95%
    • Dietary fat load
      +4detractor · 95%
    • Spicy / capsaicin
      +3.9detractor · 95%
    • Alcohol
      -2.5no signal · 53%
    • Simple carbohydrates
      +1.3no signal · 24%
    • Insoluble fibre
      -0.8no signal · 15%

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Butyrate / short-chain fatty acid production 80
      • MicrobiomeButyrate capacity 28/100
      • MicrobiomeF. prausnitzii depleted
      • Daily logFibre intake low in recent food logs
    • Inflammatory signalling 65
      • DNAIL6 -174 variant raises baseline inflammatory tone
      • BloodInflammatory load index 57
      • WearableHRV 38 ms, trending down
    • Autonomic recovery 65
      • WearableResting HR 73 bpm
      • Wearable967 steps/day
      • WearableShort sleep window
    • Mucosal barrier integrity 60
      • DNAFUT2 non-secretor lowers mucosal fucosylation
      • Daily logGI symptom score 61 and rising
      • WearableSleep 5.9 h, below personal baseline
    • Drug metabolism and exposure 20
      • BloodToxicity index 50
    DNA
    Fictional pharmacogenomic panel
    • FUT2 rs601338 AA (non-secretor)
      Reduced mucosal fucosylation
    • IL6 -174 G/C
      Higher inflammatory tone
    • CYP2D6 Rapid metabolizer
      Expected exposure
    Microbiome
    Shannon diversity 3 · butyrate capacity 28/100
    • Akkermansia muciniphilaNormal
    • Faecalibacterium prausnitziiLow
    • Bacteroides fragilisNormal
    • Bifidobacterium longumLow
    • EnterobacteriaceaeHigh
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    37 ms
    Sleep
    6.4 h
    Steps
    1,304
    Resting HR
    71 bpm
    Daily log: GI score 61, nutritional resilience 40, adherence 64.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
    • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Track each bowel movement today: time, stool form, urgency, overnight waking
    • A 15-minute walk after lunch
    • Protect a 7.5-hour sleep window; screens off 30 minutes before
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • Electrolyte solution, one sachet after any loose stool
    • Fictional demo item: oral nutrition supplement with lunch

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0138849%S17CR-01improved59
    P-0169647%S20CR-01improved59
    P-0137144%S06CR-01improved63
    P-0169942%S04GI-04improved69
    P-0183540%S17CR-01improved56
    P-0144238%S13CR-01improved61
    P-0170838%S07CR-01improved59
    P-0163537%S02GI-04improved49
    P-0187737%S01CR-01improved67
    P-0161136%S14GI-04improved44
    P-0134935%S14GI-04improved38
    P-0145235%S02GI-04improved46